Literature DB >> 20858074

Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir.

Ha T Nguyen, Alicia M Fry, P Ann Loveless, Alexander I Klimov, Larisa V Gubareva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20858074     DOI： 10.1086/656439

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  43 in total

1.  Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.

Authors:  Elena A Govorkova; Bindumadhav M Marathe; Ashley Prevost; Jerold E Rehg; Robert G Webster
Journal:  Antiviral Res       Date:  2011-05-27       Impact factor: 5.970

2.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.

Authors:  Rachel R Higgins; Melissa Beniprashad; Eddie Chong-King; Yan Li; Nathalie Bastien; Donald E Low; Jonathan B Gubbay
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

4.  Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.

Authors:  Yi Lu; Taijiao Jiang
Journal:  Protein Cell       Date:  2013-04-15       Impact factor: 14.870

5.  Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.

Authors:  Min-Suk Song; Bindumadhav M Marathe; Gyanendra Kumar; Sook-San Wong; Adam Rubrum; Mark Zanin; Young-Ki Choi; Robert G Webster; Elena A Govorkova; Richard J Webby
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

6.  Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Authors:  Andrés Pizzorno; Yacine Abed; Xavier Bouhy; Edith Beaulieu; Corey Mallett; Rupert Russell; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

7.  Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Authors:  Elena A Govorkova; Tatiana Baranovich; Patrick Seiler; Jianling Armstrong; Andrew Burnham; Yi Guan; Malik Peiris; Richard J Webby; Robert G Webster
Journal:  Antiviral Res       Date:  2013-02-28       Impact factor: 5.970

8.  A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.

Authors:  Lan Huang; Yang Cao; Jianfang Zhou; Kun Qin; Wenfei Zhu; Yun Zhu; Lei Yang; Dayan Wang; Hong Wei; Yuelong Shu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

9.  Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.

Authors:  Phillip J Yates; Nalini Mehta; Joseph Horton; Margaret Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.

Authors:  Yan Wu; Feng Gao; Jianxun Qi; Yuhai Bi; Lifeng Fu; Sankar Mohan; Yuhang Chen; Xuebing Li; B Mario Pinto; Christopher J Vavricka; Po Tien; George F Gao
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.